“My goal was very simple. Five years from now, there will be X number of more fathers, brothers, grandfathers who will be having dinners with their families because of what I'm doing, because I will find the cancer early and hopefully make an impact,” says Ashutosh Tewari, MD.
"Overall, our conclusion is, in this real-world analyses, more patients treated with apalutamide survive by 24 months following treatment initiation compared to enzalutamide," says Mehmet Asim Bilen, MD.
"It sounds so cheesy to just say it, but if you're really feeling grateful, you can't feel anything of a lower vibration or frequency at the same time," says Anne M. Suskind, MD, MS, FACS, FPMRS.
"In other words, we expected a higher infection rate after transrectal biopsy, however that 1.4% with our current sample size, we weren't powered to detect a significant difference," says Jim C. Hu, MD, MPH.
"I think it's important to try to mix up your visits with patients that you think might be a little shorter, like a vasectomy consult, vs a new patient visit for infertility that may take a little bit longer, so that you don't run over time," says Helen L. Bernie, DO, MPH.
A panel of experts in prostate cancer present the case of a 51-year-old man with high-risk localized prostate cancer.
Dr Helfand and panelists outline the incorporation of multidisciplinary approaches to the management of prostate cancer.
"Male residents do about 100 more cases over the 4 years of urology-specific training than female residents, which is a significant difference," says Kathryn Marchetti, MD.
“We see the pathways of PD-1 resistance being explored across oncology. Kidney cancer is not especially leading the way on that,” says Mayer Fishman, MD, PhD.
“We looked at MRD negative patients, MRD positive patients, and their ultimate clinical response to see if it could be predictive of recurrence-free survival,” says Vikram M. Narayan, MD.
"What we found was that the obedience to the upgrading criteria of PI-RADS as they are today resulted in a better overall outcome for all the patients that were included in the study," says Leonardo Kayat Bittencourt, MD, PhD.
“The American Cancer Society suspects that over 300,000 men will be newly diagnosed with prostate cancer this year, which is still a lot,” says Adam B. Weiner, MD.
"I think people don't understand how exhausting it is for people to manage these symptoms day in and day out," says Leslie Rickey, MD, MPH.
"In this study, we found no difference in patient-reported bowel toxicity in men receiving radiation plus relugolix vs radiation plus leuprolide," says Sagar A. Patel, MD.
"Real-world data has a real place in demonstrating some of these findings and allowing us to ask better questions," says Bogdana Schmidt, MD, MPH.
“I think that having the clinical context such as the PSA, the Gleason score, the other features that assess the aggressiveness of the disease can really help with some of these subtle findings that can be found on PET imaging,” says Daniel Spratt, MD.
"There's...this concept of the virtualist; truly, the virtual urologist who has a potentially full-time telehealth practice but geared toward really delivering care, and these positions exist," says Kara L. Watts, MD.
Clinical oncologists share their best practices for the utilization of PSMA-targeted agents in patients with prostate cancer.
A comprehensive discussion surrounding the clinical development of PSMA-targeted therapies for patients with prostate cancer.
"The SPICI study is a randomized phase 3 [trial] asking the question of de-escalation," says Laurence Albiges, MD, PhD.
"We hope that this study will build a roadmap to personalized therapeutic advice for patients with advanced prostate cancer and potentially will improve their quality of life and outcomes," says Antonina Mitrofanova, PhD.
“When we compared the performance of the 4Kscore with and without the race coefficient, we found that this coefficient improved the calibration or accuracy of this model,” says Helen Y. Hougen, MD.
"This may be a way of treating earlier stage aggressive prostate cancer with chemotherapy and selecting patients based upon their biological profiles," says Daniel P. Petrylak, MD.
Kevin M. Wymer, MD, shares the take-home messages from the recent Urology paper, “Evaluation of Private Payer and Patient Out of Pocket Costs Associated with the Surgical Management of Benign Prostatic Hyperplasia.”
In this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Expert urologists discuss the impact of their formulary on prescribing abiraterone for metastatic castration-resistant prostate cancer (mCRPC), emphasizing its use in special patient populations and the importance of accessibility. They highlight the role of educational support and collaboration with manufacturers in facilitating access to treatments not typically included in the formulary, especially for unique patient groups. They emphasize the importance of manufacturer collaboration, Medicare changes, and specialized programs for aiding low-income seniors, underscoring the commitment to enhancing patient access and compliance in healthcare.
Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber discuss the goals and assessment methods for overactive bladder (OAB) pharmacological treatments, including how they monitor and address refractory or nonresponsive cases. They explore the real-world rates of medication failure, particularly with anticholinergics, and delve into the decision-making process behind considering alternative therapies, focusing on factors that prompt a change in treatment, especially for specific patient populations. The discussion includes insights on when and why to shift from standard OAB medications to other therapeutic options.
In this episode, experts review safety concerns, drug interactions, and common adverse effects (AEs) associated with overactive bladder (OAB) medications. They discuss the impact of AEs like constipation, hypertension, and dry mouth on patient quality of life, strategies for managing these effects, and circumstances warranting a change in treatment. The experts also examine recent clinical evidence linking anti-cholinergic treatments to an increased risk of dementia in older patients, discussing its implications for clinical practice and strategies for urologists to remain vigilant about such safety concerns.
"I think probably the area getting the most attention nowadays is advances in robotic and minimally invasive surgery," says Miriam Harel, MD.
